Target intelligence / Profile preview

Aquaporin-9 (AQP9)

Target
AQP9
Molecular classification
Transporter, Channel protein, Aquaglyceroporin (subfamily of aquaporins), Major intrinsic protein family
01

Overview

Aquaporin-9 is a membrane channel protein encoded by the AQP9 gene in humans. It belongs to the aquaglyceroporin subfamily within the major intrinsic protein family. Unlike classical aquaporins that primarily conduct water, Aquaporin-9 facilitates the passage of a broad range of noncharged solutes including glycerol, urea, lactate, purines, pyrimidines, arsenite, and possibly ammonium. It forms homotetrameric channels in cell membranes—each monomer acting independently—and is especially important for hepatic uptake of glycerol supporting gluconeogenesis. In addition to its metabolic roles in liver cells (hepatocytes), it may participate in specialized functions such as immunological responses by leukocytes and protection against arsenic toxicity through excretion pathways. The structure features six transmembrane domains with intracellular N- and C-termini typical for aquaporins.

Other names
AQP-9Aquaglyceroporin 9Major intrinsic protein 9 (less common)
02

Mechanism of action

Potential mechanisms for future drugs could include inhibition or modulation of channel activity to alter water/glycerol/solute flux across membranes.

03

Biological functions

Water transport across cell membranesGlycerol transport (especially in hepatocytes)Urea transport and extrusionOsmotic water permeability regulationTransport of other small, non-charged solutes (e.g., lactate, purines, pyrimidines, arsenite)Possible role in immune response and bactericidal activity
04

Disease associations

Cancer (implicated in some studies)Inflammation (possible involvement via leukocyte function)Metabolic disorders related to glycerol or urea metabolism
05

Safety considerations

Potential safety concerns with targeting AQP9 may include disruption of normal water and solute homeostasis, metabolic disturbances due to altered glycerol/urea/lactate handling, and possible effects on immune function. These are theoretical based on its physiological roles.
06

Interacting drugs

No specific approved drugs are currently known to directly target Aquaporin-9. Research is ongoing into modulators for aquaporins as a class.
07

Biomarkers

No established clinical biomarkers for patient selection or efficacy monitoring specific to AQP9 at this time; research is ongoing.

Beyond the preview

Go deeper on Aquaporin-9 (AQP9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aquaporin-9 (AQP9).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call